Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

Details

Language :

English

ISSN :

00064971 and 15280020

Volume :

140

Issue :

Supplement 1

Database :

Supplemental Index

Journal :

Blood

Publication Type :

Periodical

Accession number :

ejs61220036

Full Text :

https://doi.org/10.1182/blood-2022-160338